Millets National Media Portal
Millets National Media Portal
HbA1c (glycated hemoglobin) reflects average blood glucose over the preceding 2–3 months and is the gold-standard marker of long-term diabetes control. Foxtail millet and sorghum have demonstrated the most consistent HbA1c-lowering effects in clinical research. A 12-week randomized controlled trial published in Frontiers in Nutrition (2021) found that type 2 diabetic patients who replaced 50% of their dietary staple with foxtail millet experienced a statistically significant reduction in HbA1c from a baseline of 8.1% to 7.4% — a clinically meaningful 0.7 percentage point reduction. This magnitude of HbA1c reduction is comparable to some first-line oral antidiabetic medications and is associated with a 35% reduction in diabetes-related complications risk.
Key Points
Foxtail millet (12-week study): reduced HbA1c by 0.7 percentage points (8.1% → 7.4%), comparable to oral antidiabetic drug effects
Sorghum consumption for 16 weeks reduced HbA1c by 0.5 percentage points in prediabetic and early diabetic patients
Finger millet tannins reduce α-glucosidase activity, producing consistent daily glucose reductions that cumulatively lower HbA1c
Maximum HbA1c benefits require 10–16 weeks of sustained millet consumption, as HbA1c reflects a 3-month average
Replacing only 50% of refined grain intake with millets produces significant HbA1c improvements without complete dietary overhaul
Evidence Base
Frontiers in Nutrition (2021) and PMC (2023) systematic reviews confirm that foxtail millet and sorghum produce clinically significant HbA1c reductions of 0.5–0.7% over 12–16 weeks, equivalent to pharmacological interventions but without side effects.
© 2023 - 2026 Millets News. All rights reserved.
